An Early Prospective Study of the Traq™ Device for Characterization of Binocular Ocular Function in Normal Subjects and Subjects With Recent Traumatic Brain Injury

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorRebiscan, Inc.

About this trial

The early prospective study of Traq™ (an investigational binocular ophthalmic neurodiagnostic device) will measure binocular ocular functions (bilateral foveal fixation, foveal binocularity, and fovea-tracked saccadic latency) in normal subjects and those with history of mild-to moderate traumatic brain injury (mTBI).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 12 years or older at the time of enrollment.

Able to understand and sign an informed consent form (or with parent/guardian for subjects less than 18 years of age).

Willing and able to complete all required study visits and test assessments.

Subjects with no history of traumatic brain injury (normal arm).

Disqualifiers

Concurrent participation in another drug or device clinical investigation.

Subject with a history of eye disease which could reduce, or limit reflected polarized light from the retina, such as corneal scarring, cataract, glaucoma, degenerative retinal conditions (e.g., age-related macular degeneration, diabetic retinopathy), or other conditions which may decrease device signal reflectance.

Subjects who are pregnant, planning to become pregnant, or are breastfeeding.

Trial population

Eye care clinic patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Binocular ophthalmic neurodiagnostic device

    Device

    Participants will undergo non-invasive binocular ophthalmic neurodiagnostic measurements and ocular assessments. No treatment or intervention will be administered as part of the study.

Treatment groups

10 Participants
are divided into 2 treatment groups
Group A: Head trauma group1 intervention
Group B: Controls1 intervention

Trial outcomes

Primary outcomes

1

Device Metrics

A composite Traq score will be calculated on a scale of 0.00-to-2.00 at each visit. The score will be a calculated combination of the following, additional outcome measures: * Bilateral foveal fixation * Foveal binocularity * Fovea-tracked saccadic latency

Time frame
Four individual scans through study completion: Day 0, Day 30, Day 60, Day 90.
2

Device Metrics

Bilateral foveal fixation will be measured as a percentage (from 0.00-1.00%) of time in which both eyes fixate together during the scan.

Time frame
Four individual scans through study completion: Day 0, Day 30, Day 60, Day 90.
3

Foveal fixation

The device will capture each individual eye's ability to fixate as a percentage (from 0.00 to 1.00) of time during the scan. A result will be provided for each individual eye.

Time frame
Four individual scans through study completion: Day 0, Day 30, Day 60, Day 90.
4

Device outputs

Fovea-tracked saccadic latency will be calculated in milliseconds to measure when fixation is attained and lost throughout the scan.

Time frame
Four individual scans through study completion: Day 0, Day 30, Day 60, Day 90.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.